Immunotherapy Vaccine and Herceptin in Breast Cancer

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

January 31, 2016

Study Completion Date

January 31, 2017

Conditions

Breastcancer

Interventions

DRUG

GP2 peptide + GM-CSF vaccine plus trastuzumab

HLA-A2+/A3+ subjects are given the GP2 peptide vaccine plus trastuzumab

DRUG

Trastuzumab

HLA-A2-/A3- patients are followed as controls receiving trastuzumab only.